• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intec Pharma, Decoy Biosystems agree to merger

March 16, 2021 By Sean Whooley

Intec Pharma Decoy BiosystemsIntec Pharma (NSDQ:NTEC) announced that it entered into a definitive agreement over a merger with Decoy Biosystems.

Jerusalem-based Intec Pharma said in a news release that the combined company is slated to grow an immunotherapy platform to battle a variety of tumor types and chronic viral infections with Decoy bringing to the table multi-targeted products that prime both innate and adaptive anti-tumor and anti-viral immune responses.

Intec develops the Accordion Pill, an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development through gastric retention and specific release mechanism.

Decoy previously held a pre-investigational new drug meeting with the FDA ahead of its plans to file an IND in the second half of this year. The company is looking to launch a Phase 1 clinical trial in 2022 to observe its therapies in targeting tumors and lymphomas.

Under the agreement, upon completion of the merger, former Decoy stockholders are expected to own approximately 75% of the combined company, while Intec shareholders will own the other 25% or so.

The actual allocation will be subject to adjustment based on the companies’ net cash balance at the time of closing and the amount of closing financial raised. Both companies’ boards approved the transaction, which is expected to close in the third quarter of 2021, subject to shareholder approval, the domestication of Intec Pharma to Delaware, the disposition of Intec’s Accordion Pill business, the raising of closing financing and the continued listing on the Nasdaq, along with other customary closing conditions.

Intec CEO Jeffrey Meckler will lead the combined company as CEO with Decoy founder & CEO Michael Newman serving as CSO and Dr. Roger Pomerantz holding the role of chairman. The board will have eight members, five of which being current members of Intec’s board, with the other three serving on Decoy’s board.

“Decoy’s bacteria-based platform is a novel modality which has the potential to dramatically change how we treat cancer and chronic viral diseases,” Pomerantz said in the release.

“This transformative transaction provides Intec with a robust clinical pipeline based on a novel immunotherapy platform and gives Intec entrée into the exciting area of immuno-oncology,” added Meckler. “Our transition into immune-oncology leverages Intec’s senior-level expertise and offers an exciting, potential value-creating opportunity for our shareholders.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: Decoy Biosystems, Intec Pharma

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS